Loading...
•
Dec 31, 2024
Arbutus Q4 2024 Earnings Report
Arbutus reported a narrowed net loss and lower revenue in Q4 2024, while maintaining a strong cash position.
Key Takeaways
Arbutus Biopharma reported Q4 2024 revenue of $1.57 million and an EPS loss of -$0.07, outperforming expectations slightly. The company continued to manage its cash position effectively, with $122.62 million in cash, cash equivalents, and investments. Key developments included pipeline evaluations and corporate restructuring.
Revenue for Q4 2024 was $1.57 million, down 26.71% year-over-year.
EPS loss of -$0.07 beat analyst expectations by $0.01.
Cash, cash equivalents, and investments totaled $122.62 million as of December 31, 2024.
Implemented a 57% workforce reduction and strategic pipeline evaluation to streamline operations.
Arbutus
Arbutus
Arbutus Revenue by Segment
Revenue by Segment
Collab & License Rev Revenue
CapyFin.comNon-Cash Royalty Rev Revenue
CapyFin.com Forward Guidance
Arbutus expects to reduce its net cash burn in 2025 while progressing the development of its HBV therapies and advancing litigation matters.
Positive Outlook
- Significant workforce reduction to optimize operations.
- Strong cash reserves provide operational runway.
- Pipeline evaluation underway to focus on value-driving assets.
- Phase 2b trial of imdusiran under consideration.
- Continued legal efforts to defend LNP IP rights globally.
Challenges Ahead
- Revenue declined due to lower royalty and license income.
- Ongoing litigation adds uncertainty and cost.
- Reduced internal research following lab closure.
- Restructuring charges expected in Q1 2025.
- Operational downsizing may impact development speed.
Revenue & Expenses
Visualization of income flow from segment revenue to net income